Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis

<jats:sec> <jats:title>Background and aim</jats:title> <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is an alternative description and classification of non-alcoholic fatty liver disease (NAFLD) that may have better utility than NAFLD in clinical practice. We performed a meta-analysis to quantify the magnitude of the association between MAFLD and risk of both prevalent and incident chronic kidney disease (CKD).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We systematically searched PubMed, Medline (OVID), Embase (OVID), Web of Science and Cochrane Library from database inception until 29 May 2022. We included observational studies examining the association between MAFLD and risk of CKD, defined by estimated glomerular filtration rate ≤60 mL/min/1.73 m<jats:sup>2</jats:sup> or presence of abnormal albuminuria. Meta-analysis was performed using random-effects models to obtain summary HRs or ORs with 95% CIs.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Seventeen observational studies with aggregate data on 845 753 participants were included in meta-analysis. In the 7 cohort studies, the pooled random-effects HR for incident CKD in patients with MAFLD was 1.29 (95% CI 1.17 to 1.41, I<jats:sup>2</jats:sup>=87.0%). In the 10 cross-sectional studies, the pooled random-effects OR for prevalent CKD in patients with MAFLD was 1.35 (95% CI 1.11 to 1.64, I<jats:sup>2</jats:sup>=92.6%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>MAFLD is significantly associated with an increased prevalence and incidence of CKD.</jats:p> </jats:sec> <jats:sec> <jats:title>PROSPERO registration number</jats:title> <jats:p>CRD42022352366.</jats:p> </jats:sec>